Serum Her2neu Levels And Detection Of Early Recurrence

In the 1996 report by Molina et al. (58), they evaluated the utility of measuring HER2 neu, carcinoembryonic antigen (CEA), and CA 15-3 in the early diagnosis of recurrence. Serial serum measurements were performed in 200 primary breast cancer patients (no evidence of residual disease) followed for 1- 4 yr with a median of 2.2 yr. Of the 89 patients who developed metastasis, 28 had a serum HER2 neu above the cutoff, 30 had a CEA that was above the normal cutoff and 47 demonstrated elevated...

References

Cell cycle and cancer. J Natl Cancer Inst 1995 87 1499-2005. 2. Gillett CE, Barnes DM. Demystified cell cycle. Mol Pathol 1998 51 310-316. 3. Barnes DM, Gillett CE. Determination of cell proliferation. J Clin Pathol Mol Pathol 1995 48 M2-M5. 4. Amadori D, Silvestrini R. Prognostic and predictive value of thymidine labelling index in breast cancer. Breast Cancer Res Treat 1998 51 267-281. 5. Daidone MG, Silvestrini R. Prognostic and predictive role of proliferation...

Upa and pai1 in breast cancer

Multiple studies have shown increased expression of both uPA and PAI-1 in breast carcinomas vis-a vis nonmalignant breast tissue (15-17). The mechanism(s) responsible for this enhanced expression in malignancy are unknown. In breast cell lines in culture, various hormones and growth factors have been shown to modulate uPA expression (Table 1). Other factors known to alter uPA expression in vitro include methylation of gene promoter regions (28) and specific transcription factors, especially...

Mda231 Mda175 Skbr3

0 No discernible membrane staining 1+ Faint barely perceptible, incomplete membrane staining 3+ Moderate strong complete membrane staining Assay (CTA) subsequently utilized to select patients for the Herceptin development trials. 4D5 was the antibody selected for the assay with a standard antimouse antibody and an avidin-biotin horseradish peroxidase complex. The antigen retrieval consisted of limited protease treatment. The conditions for the assay were standardized to obtain a reliable and...

Methods Of Determining Her2neu STATUS

The most widely accepted method for measuring HER2 neu protein (p185) overexpression is immunohistochemistry (IHC) (16,17) whereas the number of HER2 neu gene copies or gene amplification is determined by using a fluorescence in situ hybridization (FISH) assay (16,17). Enzyme-linked immunoabsorbent assays (ELISAs) have been used since 1991 to quantitate either the full length p185 in tumor tissue (7) or the soluble circulating HER2 neu ECD in serum (8) or plasma (7). However, there are...

Expression of the egfr family in breast cancer

The EGFR family consists of four closely related genes c-erb-B1 or EGFR, c-erb-B2 or HER2, c-erb-B3 or HER3, and c-erb-B4 or HER4. These receptor proteins are glycosylated and share a similar primary structure consisting of an extracellular, ligand-binding domain (which has two cysteine-rich regions), a single transmembrane region, a short juxta-membrane sequence, and an intracellular domain that contains a tyrosine-kinase domain flanked by a large hydrophilic carboxyl tail. The carboxyl tail...

Prevalence Of Circulating Her2neu Levels In Breast Cancer

We reviewed a total of 55 publications from which data on the prevalence (7,8,22-73) of elevated levels of circulating HER2 neu could be extracted. The data are summarized in Fig. 2 and represent circulating HER2 neu ECD measurements in more than 6500 patients with breast cancer. A review of 24 references used to evaluate ECD levels in primary breast cancer showed that approx 18.5 of the 1923 patients had circulating HER2 neu ECD levels that were above the control cutoff described in each...

Info

MI, Mitotic figure index count M V, volume corrected mitotic index r, median correlation or regression coefficients. Space constraints do not permit us to mention all the articles whose results contributed to the data reported in the table. MI, Mitotic figure index count M V, volume corrected mitotic index r, median correlation or regression coefficients. Space constraints do not permit us to mention all the articles whose results contributed to the data reported in the table. capability of...

Giampietro Gasparini md Daniel F Hayes md

Cancer Drug Discovery and Development Cancer Drug Resistance, edited by Beverly A. Teicher, 2006 Histone Deacetylases Transcriptional Regulation and Other Cellular Functions, edited by Eric Verdin, 2006 Immunotherapy of Cancer, edited by Mary L. Disis, 2006 Biomarkers in Breast Cancer Molecular Diagnostics for Predicting and Monitoring Therapeutic Effect, edited by Giampietro Gasparini and Daniel F. Hayes, 2005 Protein Tyrosine Kinases From Inhibitors to Useful Drugs, edited by Doriana Fabbro...